Get started
Author

Alizée Viandier

Observed name: Alizee Viandier
ORCID: 0009-0001-7912-3585
Observed ORCID: 0009-0001-7912-3585
OpenAlex ID: A5068935998
NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2025 · Sara Majocchi, Pauline Lloveras, et al. · Cancer Immunology Research · 12
PDF
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
2024 · Anja Seckinger, Vanessa Buatois, et al. · Frontiers in Immunology · 10
PDF
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies
2025 · Julien Montorfani, Eric Hatterer, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
265 CD47xPD-L1 bispecific antibodies for cancer therapy
2021 · Xavier Chauchet, Elise Pernarrieta, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S14 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S17 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S12 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S16 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S10 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S11 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S15 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S02 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S08 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Works count: 57
Citation count: 26
H-index: 3
I10-index: 2
Year
Topic
Type